Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BeiGene Ltd ( (HK:6160) ) has shared an announcement.
BeOne Medicines Ltd., a Swiss corporation, has made an overseas regulatory announcement regarding its Form 8-K12G3 filing with the U.S. Securities and Exchange Commission. This filing, dated May 27, 2025, is part of the company’s compliance with the Securities Exchange Act of 1934. The announcement underscores BeOne Medicines’ commitment to maintaining transparency and regulatory compliance, which may impact its market perception and investor confidence.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,789,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$236.3B
See more data about 6160 stock on TipRanks’ Stock Analysis page.